Johnson & Johnson announced its fourth-quarter and full-year 2024 financial results, reporting strong sales growth and significant progress in its pipeline of innovative medicines and MedTech solutions. Fourth-quarter sales reached $22.5 billion, a 5.3% increase from the previous year, while full-year sales grew 4.3% to $88.8 billion. Adjusted operational growth excluding the COVID-19 vaccine was 7.0% for the full year.

Key highlights include:

Fourth-quarter performance included reported earnings per share (EPS) of $1.41 and adjusted EPS of $2.04, with a $0.22 impact from acquired in-process research and development (IPR&D) charges related to the V-Wave acquisition.

Full-year performance featured reported EPS of $5.79 and adjusted EPS of $9.98, with a $0.67 impact from acquired IPR&D charges on various transactions. Free cash flow for the year was approximately $19.8 billion.

The Innovative Medicine segment achieved 5.7 percent adjusted operational sales growth, excluding COVID-19 vaccines, driven by products like Darzalex, Tremfya, and Carvykti. The MedTech segment grew by 6.2 percent, supported by strong demand for cardiovascular and wound closure products.

Pipeline advances included U.S. FDA approval of Spravato for treatment-resistant depression, the European Commission's approval of Lazcluze in combination with Rybrevant for advanced non-small cell lung cancer, and progress with Ottava, the company's robotic surgical system.

For 2025, Johnson & Johnson projects operational sales growth of 2.5 to 3.5 percent, with adjusted operational EPS expected to range between $10.75 and $10.95, reflecting an 8.7 percent increase at the midpoint. The company’s commitment to innovation and its robust pipeline positions it to address unmet medical needs across various therapeutic areas.